更新于：2024-06-24

CBP-501

更新于：2024-06-24

概要

研发状态

概要

基本信息

药物类型

合成多肽

别名

Cdc-25C-phosphatase (211-221)、H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt、CBP 501

+ [1]

靶点

CaM

作用机制

CaM调节剂(钙调蛋白调节剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症

胰腺癌

非在研适应症

晚期恶性实体瘤恶性胸膜间皮瘤转移性非鳞状非小细胞肺癌

原研机构

CanBas Co., Ltd.

在研机构

CanBas Co., Ltd.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

结构

分子式C86H122F5N29O17

InChIKeyDEZJGRPRBZSAKI-KMGSDFBDSA-N

CAS号565434-85-7

序列信息

Sequence Code 527059245

关联

项与 CBP-501 相关的临床试验

NCT04953962 / Completed临床2期

Multicenter, Randomized, Parallel Group, Phase 2 to Establish the Efficacy and Safety of Combinations of CBP501, Cisplatin, and Nivolumab for ≥3rd Line Treatment of Patients With Exocrine Pancreatic Cancer and WBC <10,000/mm3 at Screening

Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC < 10,000/mm3 at screening.

开始日期2021-12-18

申办/合作机构

CanBas Co., Ltd.

NCT03113188 / Completed临床1期

Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors

This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.

开始日期2017-10-25

申办/合作机构

CanBas Co., Ltd.

NCT00942825 / Completed临床2期

Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC)

This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous NSCLC as consecutive i.v. infusions according to a once-every-3-weeks schedule.
The protocol will evaluate full-dose cisplatin and pemetrexed with or without CBP501. Patients will be randomized in a 1:1 ratio to pemetrexed, cisplatin and CBP501 (Arm A) or pemetrexed and cisplatin (Arm B). Randomization will be stratified according to whether or not patients are eligible for bevacizumab therapy.
Preclinical and clinical findings that support this protocol are:
CBP501 has exhibited interesting preclinical activity in various lung cancer cell lines.
Synergism was documented with CBP501/cisplatin in the preclinical studies with lung cancer cell lines.
The dose-limiting toxicity (DLT) of CBP501 was rapid onset allergic reaction, as was suggested by preclinical toxicology. Other toxicities were quite limited. No evidence of potentiation of either CBP501 or cisplatin toxicity was found in the combination phase I trial, and the toxicity of the combination, primarily related to cisplatin, is manageable. It is expected that CBP501 and pemetrexed will display non-overlapping toxicity profiles in combination, given that hematological toxicity and gastrointestinal toxicity are the principal toxicity types of the latter.
Given the acceptable safety of the cisplatin/ pemetrexed combination, it is anticipated that the addition of CBP501 to this combination can be evaluated without excessive risk in the phase II programs.
The phase I study of CBP501 in combination with pemetrexed/cisplatin (phase I part of the mesothelioma program) did not show DLTs or evidence of enhancement of toxicities with the triplet combination. The RD of CBP501 25 mg/m², cisplatin 75 mg/m² and pemetrexed 500 mg/m² is currently in use in the phase II study with first line mesothelioma patients.
Hints of activity were observed during the phase I study with CBP501 and cisplatin.
No pharmacokinetics (PK) interaction was documented between cisplatin and CBP501.

开始日期2009-04-01

申办/合作机构

CanBas Co., Ltd.

100 项与 CBP-501 相关的临床结果

登录后查看更多信息

100 项与 CBP-501 相关的转化医学

登录后查看更多信息

100 项与 CBP-501 相关的专利（医药）

登录后查看更多信息

项与 CBP-501 相关的文献（医药）

2023-06-01·Psychopharmacology

The effects of serotonergic psychedelics in synaptic and intrinsic properties of neurons in layer II/III of the orbitofrontal cortex.

Article

作者: Yu, Zhi-Peng ; Muhetaer, Kadeliya ; Tang, Zi-Hang ; Li, Qiong ; Xu, Peng ; Zhang, Xiao-Qin ; Wang, Zheng-Chun ; Shen, Hao-Wei

RATIONALE:

Serotonergic psychedelics show promise in the treatment of psychiatric disorders, including obsessive-compulsive disorder. Dysfunction of the orbitofrontal cortex (OFc) has been implicated in the pathophysiology of compulsive behavior, which might be a key region for the efficacy of psychedelics. However, the effects of psychedelics on the neural activities and local excitation/inhibition (E/I) balance in the OFc are unclear.

OBJECTIVES:

This study aimed to investigate how 25C-NBOMe, a substituted phenethylamine psychedelic, regulated the synaptic and intrinsic properties of neurons in layer II/III of the OFc.

METHODS:

Acute brain slices containing the OFc of adult male Sprague Dawley rats were used for ex vivo whole-cell recording. The synaptic and intrinsic properties of neurons were monitored using voltage and current clamps, respectively. Electrically evoked action potential (eAP) was used to measure synaptic-driven pyramidal activity.

RESULTS:

25C-NBOMe enhanced spontaneous neurotransmission at glutamatergic synapses but diminished that in GABAergic synapses through the 5-HT_2A receptor. 25C-NBOMe also increased both evoked excitatory currents and evoked action potentials. Moreover, 25C-NBOMe promoted the excitability of pyramidal neurons but not fast-spiking neurons. Either inhibiting G protein-gated inwardly rectifying potassium channels or activating protein kinase C significantly obstructed the facilitative effect of 25C-NBOMe on the intrinsic excitability of pyramidal neurons.

CONCLUSIONS:

This work reveals the multiple roles of 25C-NBOMe in modulating synaptic and neuronal function in the OFc, which collectively promotes local E/I ratios.

2023-04-01·Neuropharmacology

The high frequency oscillation in orbitofrontal cortex is susceptible to phenethylamine psychedelic 25C–NBOMe in male rats

Article

作者: Yu, Zhi-Peng ; Wu, Zhou-Xiao ; Tang, Zi-Hang ; Xu, Peng ; Wang, Zheng-Chun ; Zhang, Xiao-Qin ; Li, Qiong ; Shen, Hao-Wei

Serotoninergic psychedelics induced extensive alterations in perception and cognition, which has been attributable to its disruptive effect on oscillatory rhythms of prefrontal cortex. However, there is a lack of information how serotoninergic psychedelics affect the intra-prefrontal network, which intrinsically interact to accomplish perceptual processing. Uncovering the altered neural network caused by psychedelics helps to understand the mechanisms of their psychoactive effects and contribute to develop biological markers of psychedelic effects. In present study, we investigated the effects of substituted phenethylamine psychedelic 25C-NBOMe on neural oscillations in the intra-prefrontal and hippocampal-prefrontal network. The effective dose of 25C-NBOMe (0.1 mg/kg) disrupting sensorimotor gating in male Sprague-Dawley rats was used to observe its effects on neural oscillations in the prelimbic cortex, anterior cingulate cortex, orbitofrontal cortex (OFC) and hippocampus CA1. The power of high frequency oscillation (HFO, 120-150 Hz) was potentiated by 25C-NBOMe selectively in the OFC, with peaking at 20-30 min after treatment. 25C-NBOMe strengthened HFO coherence within the intra-prefrontal, rather than hippocampal-prefrontal network. Potentiated HFO in the OFC had a strong positive correlation with the strengthened inter-prefrontal HFO coherence by 25C-NBOMe. The 25C-NBOMe-induced alterations of rhythmic patterns were prevented by pre-treatment with selective serotonin 2A receptor antagonist MDL100,907. These results demonstrate that OFC rhythmic activity in HFO is relatively susceptible to substituted phenethylamine and potentially drives drug-induced rhythmic coherence within intra-prefrontal regions. Our findings provide additional insight into the neuropathophysiology of the psychoactive effects of psychedelics and indicate that the altered HFO might be applied as a potential biological marker of psychedelic effect.

2021-01-01·Toxicology reports

Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity

Article

作者: Garavito-Aguilar, Zayra V ; Osorio-Méndez, Jhon Jairo ; Garzón-Méndez, William F ; Álvarez-Alarcón, Natalie ; Ayala-Fajardo, Adis

The NBOMe (N-2-methoxybenzyl-phenethylamines) family of compounds are synthetic hallucinogens derived from the 2C series. Although this family of compounds has been responsible for multiple cases of acute toxicity and several deaths around the world, to date there are few studies. These compounds act as potent 5-HT_2A receptor agonists, including the hallucinogen 25C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine). In this study, we first evaluated the toxicity of 25C-NBOMe in two animal models: Artemia salina and zebrafish using the lethality test of Meyer et al. (1982) modified for Artemia salina and the Fish Embryo Toxicity test (FET) for zebrafish (Danio rerio). Subsequently, we determined the behavioral and morphological effects using different concentrations of the 25C-NBOMe. As a result, we found that this substance is highly toxic according to lethality tests in both animal models. We also observe that this hallucinogen induces alterations in swimming and motility patterns in Artemia salina. Similarly, there were alterations in the motor response to a stimulus, as well as abnormal development in the zebrafish. The developmental effects of zebrafish suggest a teratogenic potential for 25C-NBOMe. Therefore, these findings are correlated with side effects, such as motor response abnormalities and muscle deterioration, clinically reported for consumers of this recreational drug. Finally, although recent studies are addressing the neurotoxicity and cardiotoxicity of 25C-NBOMe in cell cultures, to the best of our knowledge, this is the first in vivo report for 25C-NBOMe related to toxicological parameters and their global effects on development. Therefore, it could represent an advance in the study of the substance that contributes to the understanding of the effects on behavior and development in humans.

项与 CBP-501 相关的新闻（医药）

2023-01-02

·PRNewswire

Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

The prevalence of pancreatic cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline, and the growing research and development activities to develop novel therapies to treat Pancreatic Cancer drive the market. The companies developing the potential therapies in the last stage of development include FibroGen, Eli Lilly and Company, CARsgen Therapeutics, and several others. LAS VEGAS, Jan. 2, 2023 /PRNewswire/ -- DelveInsight's ' Pancreatic Cancer Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline pancreatic cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the pancreatic cancer pipeline domain. Key Takeaways from the Pancreatic Cancer Pipeline Report DelveInsight's pancreatic cancer pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for pancreatic cancer treatment. Key pancreatic cancer companies such as FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc.Amgen, Biomea Fusion, and others are evaluating pancreatic cancer drugs to improve the treatment landscape. Promising pancreatic cancer pipeline therapies in various stages of development include Pamrevlumab, Niraparib, CT041, APG-1387, BNT141, ENB003, NUV-868, MCLA-128, LUM015, tisotumab vedotin, OMT-111, tusamitamab ravtansine, SCO-101, NGM120, CDX-301, NLM-001, TAS 102, Olaptesed pegol, BL-8040, Gimatecan, AMP945, N-803, HCW9218, BLEX 404, delolimogene mupadenorepvec, Mitoxantrone Hydrochloride Liposome injection, ABTL0812, CBP501, Pemigatinib, SHR-1701, Fluzoparib, XB2001, Cabiralizumab, EF-009, SGT-53, ABBV-927, PBP1510, Vemurafenib, siG12D-LODER, Penpulimab, GC4711, GSK2256098, L-DOS47, SBP-101, Antroquinonol, LY3214996, Sintilimab, RP72, PBP1510, IOA-289, U87, MVT-5873, SHR-A1904, iNeo-Vac-P01, iNeo-Vac-P01, TQB2858, Siltuximab, AGEN1423, AB680, AMG 199, BMF-219, and others. In December 2022, Targovax ASA announced that it has entered into a collaboration agreement with The University of Kansas Cancer Center (KU Cancer Center) and Agenus Inc. to run a clinical trial testing mutant RAS vaccine TG01 in combination with PD-1 CPI balstilimab in pancreatic cancer following surgery and standard-of-care (SoC) chemotherapy. In December 2022, Bluestar Genomics, Inc. announced the initiation of the New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies in pancreatic cancer to date. The trial will use Bluestar Genomics' proprietary epigenomic methods for the detection of the disease. In December 2022, iOnctura BV, a clinical-stage biotech developing novel cancer therapies, had been granted €17.5 million ($18.6 million) funding from the European Investment Council's (EIC) accelerator program to develop IOA-289 for pancreatic cancer.The EIC's funding consists of a grant of €2.5 million ($2.7 million) and €15 million ($16 million) of equity investment. In December 2022, In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center. The results of the trial, published in the The New England Journal of Medicine, indicate an objective response rate of 21.1% and a median time-to-response of 1.5 months, with 84% of patients experiencing disease control. Median progression-free survival was 4 months, and overall survival was 6.9 months. In December 2022, Oncolytics Biotech® Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation. In December 2022, RemeGen Co., Ltd. announced that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company's fourth, having previously been granted ODD twice for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year. In December 2022, Panbela Therapeutics, Inc. announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Panbela's application for orphan designation of ivospemin ( SBP-101) in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA). In September 2022, Qualigen Therapeutics, Inc. announced the presentation of two posters on QN-302 at the AACR 8th Special Conference on Pancreatic Cancer. The data presented include information on the compound's safety, tolerability, and efficacy in a pancreatic cancer model. The poster included preclinical toxicology data that showed QN-302 does not produce adverse toxicological reactions in mouse models at therapeutic doses. In in vitro tests, QN-302 inhibits acetylcholinesterase (AChE) by 53% and muscarinic receptor (M2) by 70% at 1 µM. Request a sample and discover the recent advances in pancreatic cancer drugs @ Pancreatic Cancer Pipeline Report The pancreatic cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage pancreatic cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the pancreatic cancer clinical trial landscape. Pancreatic Cancer Overview Pancreatic cancer develops in the pancreas tissues, an abdomen organ located behind the stomach's bottom portion. The pancreas secretes hormones that help control blood sugar and enzymes that aid digestion. Pancreatic cancer is a condition in which malignant (cancer) cells develop in pancreatic tissues. The pancreas can develop tumors in various ways, including malignant and noncancerous tumors. However, the precise causes of pancreatic cancer are unknown. Individuals diagnosed with pancreatic cancer before the tumor develops or spreads have an average life expectancy of pancreatic cancer of 3 to 3.5 years. Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, loss of appetite, fatigue, and others. A pancreatic cancer diagnosis is difficult because symptoms are frequently confused with those of other disorders, such as irritable bowel syndrome. The extent of the cancer determines the treatment of pancreatic cancer options. Pancreatic cancer treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these. Learn more about the diseases and pancreatic cancer diet @ Pancreatic Cancer Tests A snapshot of the Pancreatic Cancer Pipeline Drugs mentioned in the report: Learn more about the emerging pancreatic cancer treatment options @ Pancreatic Cancer Clinical Trials Pancreatic Cancer Therapeutics Assessment The pancreatic cancer pipeline report proffers an integral view of pancreatic cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Pancreatic Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine Therapeutics Assessment By Mechanism of Action: Connective tissue growth factor inhibitors, Poly(ADP-ribose) polymerase 1 inhibitors, Poly(ADP-ribose) polymerase 2 inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Growth differentiation factor 15 inhibitors, Endothelin B receptor antagonists, Image enhancers Key Pancreatic Cancer Companies: FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, Bayer, Genentech, Inc., Rise Biopharmaceuticals, Inc., Prestige Biopharma Limited, iOnctura, Shanghai Unicar-Therapy Bio-medicine Technology, Shanghai Hengrui Pharmaceutical Co., Ltd., Hangzhou Neoantigen Therapeutics Co., Ltd., EUSA Pharma, Inc.,Agenus Inc., Arcus Biosciences, Inc., Amgen, Biomea Fusion, and others. Key Pancreatic Cancer Pipeline Therapies: Pamrevlumab, Niraparib, CT041, APG-1387, BNT141, ENB003, NUV-868, MCLA-128, LUM015, tisotumab vedotin, OMT-111, tusamitamab ravtansine, SCO-101, NGM120, CDX-301, NLM-001, TAS 102, Olaptesed pegol, BL-8040, Gimatecan, AMP945, N-803, HCW9218, BLEX 404, delolimogene mupadenorepvec, Mitoxantrone Hydrochloride Liposome injection, ABTL0812, CBP501, Pemigatinib, SHR-1701, Fluzoparib, XB2001, Cabiralizumab, EF-009, SGT-53, ABBV-927, PBP1510, Vemurafenib, siG12D-LODER, Penpulimab, GC4711, GSK2256098, L-DOS47, SBP-101, Antroquinonol, LY3214996, Sintilimab, RP72,PBP1510, IOA-289, U87, MVT-5873, SHR-A1904, iNeo-Vac-P01, iNeo-Vac-P01, TQB2858, Siltuximab, AGEN1423, AB680, AMG 199, BMF-219, and others. Dive deep into rich insights for pancreatic cancer research; visit @ New Treatment for Pancreatic Cancer Table of Contents For further information on pancreatic cancer prevention, reach out @ Pancreatic Cancer Drug Treatment Related Reports Pancreatic Cancer Epidemiology Pancreatic Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted pancreatic cancer epidemiology in the 7MM. Pancreatic Cancer Market Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others. Advanced Pancreatic Cancer Market Advanced Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others. Advanced Pancreatic Cancer Pipeline Advanced Pancreatic Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others. Metastatic Pancreatic Cancer Market Metastatic Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others. Metastatic Pancreatic Cancer Pipeline Metastatic Pancreatic Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, including Takeda Oncology, Salspera, Eli Lilly and Company, among others. Other Trending Oncology Reports Follicular lymphoma | Indolent lymphoma | Severe Toxicities In Lymphoma | Marginal Zone Lymphoma | Vulvar Squamous Cell Carcinoma | Cholangiocarcinoma | Metastatic Cutaneous Squamous cell Carcinoma | Nasopharyngeal Carcinoma | Ductal Carcinoma in Situ | Oncolytic Virus Cancer Therapy | Cancer Cachexia | Intratumoral Cancer Therapies | Brain Cancer Related Healthcare Blogs Upcoming Oncology Drugs Oncology Market Outlook Future of Oncology Market Related Cases Studies Competitive Intelligence Market Assessment Product Assessment Epidemiology Assessment Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

快速通道孤儿药临床结果免疫疗法

2021-05-06

·GlobeNewswire

Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma

Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care Several pharmaceutical companies are developing the Checkpoint Kinase Inhibitors as one of the most promising therapies owing to the treatment of Cancer and Advanced solid tumors. DelveInsight’s ‘Checkpoint Kinase Inhibitor Pipeline Insights’ report lays out a complete view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Checkpoint Kinase Inhibitor landscape. Some of the key highlights of the Checkpoint Kinase Inhibitor Pipeline report: Got queries? Want to know more? Request for Sample @ Checkpoint Kinase Inhibitor Emerging Therapies and Forecast Checkpoint Kinases The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage. Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies. For more information on Checkpoint Kinase Inhibitors, visit Checkpoint Kinase Inhibitor Pipeline Analysis Checkpoint Kinase Inhibitor Pipeline Drugs Request for Sample to know more @ Checkpoint Kinase Inhibitor Pipeline Analysis, Key Companies and Futuristic Trends Checkpoint Kinase Inhibitor Therapeutic Assessment The Checkpoint Kinase Inhibitor Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type By Stage By Molecule Type By Route of Administration By Stage and Route of AdministrationBy Stage and Product Type Get in touch with our Business executive for Drug Pipeline Assessment and Consulting Solutions Scope of the Report Coverage: GlobalKey Players: Boehringer Ingelheim, CanBas, Vernalis, Sierra Oncology, Pharos I&BT Co, Eli Lilly and company, Sentinel Oncology, IMPACT Therapeutics, Pink Biopharma.Key Checkpoint Kinase Inhibitor Pipeline Therapies: BI 765063, CBP501, VER-250840, SRA737, PHI-101, Prexasertib, SOL 578, IMP10, and Research Programme: checkpoint kinase inhibitors. Reach out @ Checkpoint Kinase Inhibitor Pipeline: Novel therapies and Emerging Technologies Key Questions Answered in the Report Request for Webex demo of the report @ Checkpoint Kinase Inhibitor Pipeline Analysis and Emerging Trends Table of Contents Visit to know more of what’s covered @ Checkpoint Kinase Inhibitor Emerging Therapies Related Reports Global Kinase Inhibitor In Autoimmune Diseases MarketDelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases – Market Insights and Market Forecast – 2030’ report. Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer MarketDelveInsight’s ‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast-2030’ report. Cyclin-Dependent Kinase Like 5 Cdkl5 Deficiency Disorder MarketDelveInsight's "Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder - Market Insights, Epidemiology, and Market Forecast-2030" report. Pyruvate Kinase Deficiency MarketDelveInsight's "Pyruvate Kinase Deficiency - Market Insights, Epidemiology, and Market Forecast-2030" report. Bruton’s Tyrosine Kinase Btk Inhibitors Competitive Landscape Pipeline And Market AnalysisDelveInsight’s “Bruton's Tyrosine Kinase (BTK) Inhibitors – Competitive Landscape, Market and Pipeline Analysis, 2020” report. Anaplastic Lymphoma Kinase Inhibitor Pipeline InsightDelveInsight’s "Anaplastic Lymphoma Kinase (ALK) Inhibitor - Pipeline Insights, 2021" report. Thymidine Kinase 2 Deficiency Pipeline InsightDelveInsight’s "Thymidine Kinase 2 Deficiency (TK2D) Pipeline Insights, 2021" report. AXL Kinase Inhibitor Pipeline InsightDelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2021” report. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

100 项与 CBP-501 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床2期	美国	CanBas Co., Ltd.	2021-12-18
转移性非鳞状非小细胞肺癌	临床2期	美国	CanBas Co., Ltd.	2009-04-01
晚期恶性实体瘤	临床2期	美国	CanBas Co., Ltd.	2008-05-01
恶性胸膜间皮瘤	临床2期	美国	CanBas Co., Ltd.	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04953962 (Pubmed)	临床2期	胰腺癌	36	CBP501 25 mg/m2/Cisplatin/Nivolumab	憲襯鹹獵壓膚壓廠鹽遞(窪餘獵構窪糧鹽顧顧鬱) = 網齋繭糧齋顧餘鬱夢醖蓋觸醖壓製齋淵網顧艱 (獵膚鏇餘膚築選壓齋襯 ) 更多	-	2024-04-01
				CBP501 16 mg/m2/Cisplatin/Nivolumab	憲襯鹹獵壓膚壓廠鹽遞(窪餘獵構窪糧鹽顧顧鬱) = 醖獵襯積壓餘憲獵願網蓋觸醖壓製齋淵網顧艱 (獵膚鏇餘膚築選壓齋襯 ) 更多
NCT04953962 (ESMO2023) 人工标引	临床2期	胰腺癌三线	36	CBP501 25 mg/m2 + cisplatin 60 mg/m2 + nivolumab 240 mg	築淵餘範艱餘顧鹽遞鬱(窪簾遞艱鹽餘鏇齋選繭) = 鹽鬱遞鑰窪網遞鏇醖願糧廠構淵願鹽壓積艱糧 (遞齋觸遞鑰築淵鹹製夢 ) 更多	积极	2023-10-23
				CBP501 16 mg/m2 + cisplatin 60 mg/m2 + nivolumab 240 mg	築淵餘範艱餘顧鹽遞鬱(窪簾遞艱鹽餘鏇齋選繭) = 齋簾構艱淵糧築糧夢憲糧廠構淵願鹽壓積艱糧 (遞齋觸遞鑰築淵鹹製夢 ) 更多
NCT00700336 (CTgov)	临床1/2期	恶性胸膜间皮瘤 \| 晚期恶性实体瘤	69	cisplatin+CBP501+pemetrexed (Pemetrexed, Cisplatin, and CBP501: Phase 2)	構鹽醖醖製製夢襯構醖(觸窪遞艱蓋鹽顧遞鹹願) = 壓構憲憲鏇鹽觸構餘糧顧窪餘獵獵願築鹹糧蓋 (壓獵壓製製鹹淵醖鏇簾, 糧範網廠網遞廠齋衊築 ~ 積夢鹽顧餘糧願鏇築襯) 更多	-	2021-07-20
				cisplatin+pemetrexed (Pemetrexed and Cisplatin: Phase 2)	構鹽醖醖製製夢襯構醖(觸窪遞艱蓋鹽顧遞鹹願) = 鬱積壓壓艱艱範憲鏇膚顧窪餘獵獵願築鹹糧蓋 (壓獵壓製製鹹淵醖鏇簾, 醖壓鹹廠壓膚餘夢範積 ~ 簾衊鏇遞膚餘網艱觸襯) 更多
NCT03113188 (ASCO2020) 人工标引	临床1期	实体瘤	25	cisplatin+nivolumab+CBP501	醖壓憲願顧製鏇餘網醖(範顧構築鹽鬱餘鏇糧壓) = 製製夢艱遞繭鑰構鹹襯膚淵淵製蓋鏇膚廠顧淵 (餘鬱繭襯繭衊簾顧積蓋 ) 更多	积极	2020-05-29
				cisplatin+nivolumab+CBP501	膚餘壓鹹鹽範齋簾糧餘(憲夢簾製鏇夢壓艱願膚) = 繭襯襯蓋顧遞糧壓積觸窪鬱範製獵鬱窪築獵簾 (艱膚齋獵選憲觸獵鑰衊 ) 更多
NCT00942825 (CTgov)	临床2期	转移性非鳞状非小细胞肺癌	195	Cisplatin+CBP501+Pemetrexed (A CBP501 +Cisplatin + Pemetrexed)	構窪夢製願願遞願壓衊(壓構糧鹹膚築憲範鏇製) = 選顧遞憲夢蓋築襯築鹽餘遞膚願艱夢觸鏇構餘 (繭網鹹艱製鏇糧願鹽憲, 壓鑰夢願顧構廠衊簾遞 ~ 積窪艱膚選觸齋願鑰鬱) 更多	-	2017-05-24
				Cisplatin+Pemetrexed (B Cisplatin + Pemetrexed)	構窪夢製願願遞願壓衊(壓構糧鹹膚築憲範鏇製) = 簾鬱窪鑰獵鑰衊範壓簾餘遞膚願艱夢觸鏇構餘 (繭網鹹艱製鏇糧願鹽憲, 衊膚網餘憲齋壓觸鹹窪 ~ 製鑰觸觸獵餘網淵選蓋) 更多
ASCO2012	临床2期	恶性胸膜间皮瘤	65	pemetrexed/cisplatin plus CBP501 25 mg/m2 IVpemetrexed/cisplatin plus CBP501 25 mg/m2 IVpemetrexed/cisplatin plus CBP501 25 mg/m2 IV	觸鹹積觸鹹網膚襯膚壓(艱鹽鏇獵鹽膚鬱鏇鏇廠) = The most common toxicity of CBP501 is infusion-related urticaria, which is easily managed with diphenhydramine 膚衊遞艱鬱夢鏇衊積繭 (鬱積遞鏇繭襯鏇顧積網 )	-	2012-05-20
				pemetrexed/cisplatin alonepemetrexed/cisplatin alone
ASCO2008	临床1期	晚期恶性实体瘤	-	CBP501	壓鑰廠糧餘夢鏇蓋襯鹹(壓簾鑰膚醖顧鏇鏇糧顧) = 醖襯壓鏇繭築窪遞蓋鹹窪膚獵築襯壓夢選觸蓋 (鏇顧築憲憲網鬱簾鏇齋 )	-	2008-05-20